Institute of Haematology and Transfusion Medicine, Medical College Hospital, 88, College Street, Kolkata, West Bengal, 700073, India.
Department of Microbiology, Medical College Hospital, Kolkata, India.
Ann Hematol. 2021 Feb;100(2):395-403. doi: 10.1007/s00277-020-04324-8. Epub 2020 Nov 2.
Timely administration of appropriate empirical antibiotics in febrile neutropenia is crucial for favourable patient outcomes. There are guidelines in place recommending such antibiotics. However, regional variations and local epidemiological data must be evaluated to tailor the antibiotics for best possible and rational use. In this study, we audited the clinical and microbiological data of febrile neutropenic episodes occurring at a tertiary care haematology institution. Three hundred and ninety-three febrile neutropenic episodes occurring in 123 patients over a 1-year period were analysed for microbial profile, sensitivity and resistance patterns, and finally clinical outcomes. Gram-negative bacilli (GNB) blood stream infections (46.9%) were more prevalent as compared to gram-positive infections (41.9%). Overall mortality due to complicated neutropenic sepsis was 19.5% (24/123 patients). Increased resistance to carbapenems, beta-lactam beta-lactamase inhibitor combinations, aminoglycosides, fluoroquinolones, and cephalosporins were observed. Cefepime and tigecycline resistance were seen in 20% and 15% GNB isolates, respectively. Chest was the most frequent focus of infection, and acute myeloid leukaemia (AML) was the most common underlying disorder which correlated with the likelihood of death (p < 0.01). Multidrug-resistant GNB (esp. Klebsiella sp.) are still most worrisome isolates in neutropenic patients. Single-agent cefepime or piperacillin-tazobactam/tigecycline combination may be considered empirical agents. Chest infections and AML were independent predictors of poor clinical outcome in neutropenic patients. Regular audit of infections and antibiotic susceptibility data is needed to improve clinical outcomes in patients with febrile neutropenia.
在发热性中性粒细胞减少症中及时给予适当的经验性抗生素对于患者的良好预后至关重要。目前已有相关指南推荐使用这些抗生素。然而,必须评估区域差异和当地的流行病学数据,以针对最佳和合理的抗生素使用进行调整。在本研究中,我们对一家三级血液病治疗机构发生的发热性中性粒细胞减少症发作的临床和微生物数据进行了审核。对 123 例患者在 1 年内发生的 393 例发热性中性粒细胞减少症发作的微生物谱、敏感性和耐药性模式以及最终临床结果进行了分析。革兰氏阴性菌(GNB)血流感染(46.9%)比革兰氏阳性感染更为普遍(41.9%)。由于复杂的中性粒细胞减少性脓毒症导致的总死亡率为 19.5%(24/123 例患者)。观察到对碳青霉烯类、β-内酰胺酶抑制剂组合、氨基糖苷类、氟喹诺酮类和头孢菌素类的耐药性增加。20%的 GNB 分离株对头孢吡肟和替加环素耐药,15%的 GNB 分离株对头孢吡肟和替加环素耐药。胸部是最常见的感染部位,急性髓细胞白血病(AML)是最常见的基础疾病,与死亡的可能性相关(p<0.01)。多药耐药的 GNB(尤其是肺炎克雷伯菌)仍然是中性粒细胞减少症患者最令人担忧的分离株。单一药物头孢吡肟或哌拉西林-他唑巴坦/替加环素联合治疗可能被视为经验性药物。胸部感染和 AML 是中性粒细胞减少症患者临床结局不良的独立预测因素。需要定期审核感染和抗生素敏感性数据,以改善发热性中性粒细胞减少症患者的临床结局。